We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Finalizes Rule for Detaining Suspicious Drug Imports

FDA Finalizes Rule for Detaining Suspicious Drug Imports

May 30, 2014

The FDA now has the power to stop any pharmaceutical import it suspects could be adulterated or misbranded, according to a final rule that implements the agency’s new import authority.

The final rule, released Thursday, stems from a provision in the 2012 FDA Safety and Innovation Act that gives FDA officials power to detain suspected drugs. Agency officials already had the ability to detain foods and medical devices.

Under the rule, an FDA field inspector can block a drug import for up to 20 days, while the importer has five days in which to appeal the detention order. The agency can detain the products for an additional 10 days if more time is needed to initiate legal action or institute injunction proceedings. The rule goes into effect June 28.

The FDA received six comments on the proposed rule issued last July, but made no changes to the draft. The agency did respond to concerns of commenters in the rule’s summary.

One commenter noted that the term adulteration was too broad. The agency replied that it can’t change the administrative detention standard itself, and that the 1938 FD&C Act has provisions that characterize adulteration and misbranding of pharmaceuticals. “Because these terms are already well characterized, we do not believe it is necessary or appropriate to further define or modify the meaning of these terms for the purpose of this rule,” the agency said.

Another commenter was concerned that detaining pharmaceuticals could create a shortage and would be withheld from patients without due process. The agency responded that the rule gives importers an opportunity for an informal hearing within five working days after an appeal is filed. While preventing drug shortages is a priority at the agency, the FDA also is concerned about introducing adulterated or misbranded drugs into the supply chain, the summary reads.

One expert believes the new rule could create havoc for industry because agency inspectors won’t be consistent in their approaches to detaining products.

The rule enables field inspectors to detain the drugs instead of going through the agency’s compliance office, William Nychis, senior regulatory advisor for the consulting firm FDAImports.com and a 40-year agency veteran, said. The problem is “the people out in the field are generally not specialists,” he said. “Giving this authority to the field investigators will only lead to more confusion and more wrong calls.”

Don’t let the FDA detain your imports. Learn how to challenge the FDA’s findings, order Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings.

Pharmaceuticals Quality Regulatory Affairs Commercial Operations

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing